PE20121649A1 - Anticuerpos monoclonales frente a progastrina y sus usos - Google Patents

Anticuerpos monoclonales frente a progastrina y sus usos

Info

Publication number
PE20121649A1
PE20121649A1 PE2012000434A PE2012000434A PE20121649A1 PE 20121649 A1 PE20121649 A1 PE 20121649A1 PE 2012000434 A PE2012000434 A PE 2012000434A PE 2012000434 A PE2012000434 A PE 2012000434A PE 20121649 A1 PE20121649 A1 PE 20121649A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
progastrin
refers
chain variable
Prior art date
Application number
PE2012000434A
Other languages
English (en)
Inventor
Julie Pannequin
Dominique Joubert
Laure Boudier
Frederic Hollande
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121649(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Servier Lab filed Critical Inst Nat Sante Rech Med
Publication of PE20121649A1 publication Critical patent/PE20121649A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL HUMANIZADO QUE SE UNE A UNA REGION N-TERMINAL DE LA PROGASTRINA HUMANA (hPG) QUE COMPRENDE A) UNA REGION VARIABLE DE CADENA PESADA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 21, 23, 84, 86, 88, ENTRE OTROS, Y COMPRENDE LAS CDR DE VH QUE TIENEN LAS SECUENCIAS DE AMINOACIDOS DE SEQ ID Nº 1, 2, 3, ENTRE OTROS; Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 22, 24, 85, 87, 89, ENTRE OTROS, Y COMPRENDE LAS CDR DE VL QUE TIENEN LAS SECUENCIAS DE AMINOACIDOS DE SEQ ID Nº 4, 5, 6, ENTRE OTROS; EN DONDE DICHOS ANTICUERPOS SE OBTIENEN DE UN HIBRIDOMA TAL COMO 43B9G11, WE5H2G7, 6B5B11C10, 20D2C3G2, 1E9A4A4, 1E9D9B6, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER COLORRECTAL
PE2012000434A 2009-10-16 2010-10-15 Anticuerpos monoclonales frente a progastrina y sus usos PE20121649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16

Publications (1)

Publication Number Publication Date
PE20121649A1 true PE20121649A1 (es) 2012-12-08

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000434A PE20121649A1 (es) 2009-10-16 2010-10-15 Anticuerpos monoclonales frente a progastrina y sus usos

Country Status (42)

Country Link
US (7) US9611320B2 (es)
EP (2) EP3421493B1 (es)
JP (3) JP5985987B2 (es)
KR (2) KR20120091221A (es)
CN (2) CN102791735B (es)
AP (1) AP2012006262A0 (es)
AR (1) AR078659A1 (es)
AU (1) AU2010306119A1 (es)
BR (1) BR112012008818B1 (es)
CA (1) CA2777691C (es)
CL (1) CL2012000914A1 (es)
CR (1) CR20120184A (es)
CU (1) CU24196B1 (es)
CY (1) CY1120913T1 (es)
DK (1) DK2488551T3 (es)
EA (2) EA029271B1 (es)
EC (1) ECSP12011796A (es)
ES (2) ES2973217T3 (es)
GE (1) GEP201706604B (es)
GT (1) GT201200114A (es)
HN (1) HN2012000708A (es)
HR (1) HRP20181645T1 (es)
IL (2) IL219019B (es)
IN (1) IN2012DN03348A (es)
LT (1) LT2488551T (es)
MA (1) MA33747B1 (es)
MX (1) MX351635B (es)
NI (1) NI201200054A (es)
NZ (2) NZ701709A (es)
PE (1) PE20121649A1 (es)
PH (1) PH12012500711B1 (es)
PL (2) PL3421493T3 (es)
PT (1) PT2488551T (es)
RS (1) RS57966B1 (es)
SG (1) SG10201704933PA (es)
SI (1) SI2488551T1 (es)
SM (1) SMT201800628T1 (es)
TN (1) TN2012000159A1 (es)
TW (1) TWI537002B (es)
UA (1) UA106771C2 (es)
WO (1) WO2011045080A2 (es)
ZA (1) ZA201202642B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
WO2011116954A2 (en) * 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
KR101576174B1 (ko) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
JP6450381B2 (ja) * 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
MX378944B (es) 2014-04-18 2025-03-10 Univ New York State Res Found Anticuerpos de antígeno anti-tf humanizado.
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
WO2017048629A1 (en) * 2015-09-15 2017-03-23 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
CN108780091A (zh) * 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 用于检测和治疗卵巢癌的组合物和方法
KR102620651B1 (ko) * 2015-12-31 2024-01-04 신케레스 에스.에이 알.엘. 암 발생의 위험도를 평가하기 위한 조성물 및 방법
ES3011729T3 (en) 2015-12-31 2025-04-08 Ecs Progastrin Sa Compositions and methods for detecting and treating gastric cancer
SG11201908998XA (en) * 2017-03-30 2019-10-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
CN110678753B (zh) * 2017-03-30 2023-10-24 普莱戈斯瑞恩癌症有限责任公司 用于治疗肺癌的组合物和方法
DK3720879T3 (da) * 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
US20200390913A1 (en) 2017-12-08 2020-12-17 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
CN112062846A (zh) * 2020-04-27 2020-12-11 杭州博茵生物技术有限公司 一种g-17单克隆抗体及其应用
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN115724949B (zh) * 2022-12-12 2026-05-15 郑州伊美诺生物技术有限公司 一种鼠源lgG单克隆抗体及其制备方法、应用
CN116143920A (zh) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 胃泌素17的单克隆抗体及其细胞株的制备方法和应用
EP4509528A1 (en) * 2023-08-16 2025-02-19 Barrelman Biosciences LLC Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN118126177A (zh) * 2023-11-22 2024-06-04 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP2567974A3 (en) * 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
PL2040753T3 (pl) * 2006-05-22 2019-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitory progastryny w leczeniu raka okrężnicy
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
WO2011116954A2 (en) * 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
KR101576174B1 (ko) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물

Also Published As

Publication number Publication date
DK2488551T3 (en) 2018-10-08
CL2012000914A1 (es) 2012-09-14
LT2488551T (lt) 2018-10-25
EA201200597A1 (ru) 2012-12-28
EP2488551A2 (en) 2012-08-22
GT201200114A (es) 2014-08-11
PL2488551T3 (pl) 2019-01-31
US11299542B2 (en) 2022-04-12
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
MX2012004400A (es) 2012-06-27
US20220195035A1 (en) 2022-06-23
MX351635B (es) 2017-10-23
EP2488551B1 (en) 2018-07-25
SMT201800628T1 (it) 2019-01-11
JP2017212992A (ja) 2017-12-07
ES2973217T3 (es) 2024-06-19
JP5985987B2 (ja) 2016-09-06
JP2015145380A (ja) 2015-08-13
ECSP12011796A (es) 2012-06-29
EA029271B1 (ru) 2018-03-30
CR20120184A (es) 2012-08-20
MA33747B1 (fr) 2012-11-01
CU20120060A7 (es) 2013-04-19
US20110117086A1 (en) 2011-05-19
NZ701709A (en) 2016-06-24
HN2012000708A (es) 2015-06-22
UA106771C2 (uk) 2014-10-10
CU24196B1 (es) 2016-09-30
CN104628857A (zh) 2015-05-20
JP2013507138A (ja) 2013-03-04
TWI537002B (zh) 2016-06-11
TN2012000159A1 (en) 2013-12-12
EP3421493B1 (en) 2024-01-17
US20180022802A1 (en) 2018-01-25
TW201119675A (en) 2011-06-16
US20170174761A1 (en) 2017-06-22
US20170306011A1 (en) 2017-10-26
JP6272793B2 (ja) 2018-01-31
IN2012DN03348A (es) 2015-10-23
EP3421493A1 (en) 2019-01-02
CN102791735A (zh) 2012-11-21
NI201200054A (es) 2012-08-20
KR101640520B1 (ko) 2016-07-19
ES2690943T3 (es) 2018-11-23
PL3421493T3 (pl) 2024-04-29
ZA201202642B (en) 2013-06-26
KR20120091221A (ko) 2012-08-17
IL219019A0 (en) 2012-06-28
NZ599971A (en) 2014-12-24
SI2488551T1 (sl) 2019-01-31
WO2011045080A2 (en) 2011-04-21
US9611320B2 (en) 2017-04-04
AP2012006262A0 (en) 2012-06-30
US10385125B2 (en) 2019-08-20
RS57966B1 (sr) 2019-01-31
SG10201704933PA (en) 2017-07-28
EA201791876A1 (ru) 2018-01-31
PH12012500711B1 (en) 2019-04-24
IL219019B (en) 2019-05-30
HK1178183A1 (zh) 2013-09-06
CA2777691C (en) 2018-02-27
PT2488551T (pt) 2018-10-31
BR112012008818B1 (pt) 2021-10-19
CA2777691A1 (en) 2011-04-21
US10385124B2 (en) 2019-08-20
IL254004A0 (en) 2017-10-31
GEP201706604B (en) 2017-01-25
US20170306012A1 (en) 2017-10-26
KR20150082672A (ko) 2015-07-15
CY1120913T1 (el) 2019-12-11
WO2011045080A3 (en) 2011-07-07
IL254004B2 (en) 2023-06-01
EP3421493C0 (en) 2024-01-17
US10377821B2 (en) 2019-08-13
US10385126B2 (en) 2019-08-20
US20200002413A1 (en) 2020-01-02
AU2010306119A1 (en) 2012-05-03
BR112012008818A2 (en) 2018-05-22
HRP20181645T1 (hr) 2018-12-14
PH12012500711A1 (en) 2012-11-12

Similar Documents

Publication Publication Date Title
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20190976A1 (es) Anticuerpos de union a cd3
PE20130159A1 (es) Anticuerpos anti-cd40
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20141432A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20131209A1 (es) Anticuerpos anti-fap
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
AR109715A1 (es) Anticuerpos anti-cd27
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20121691A1 (es) Formulacion de anticuerpos y regimenes terapeuticos
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20120497A1 (es) Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
PE20121494A1 (es) Anticuerpos anti notch-1
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos

Legal Events

Date Code Title Description
FG Grant, registration